FibroScan™ in Pediatric Cholestatic Liver Disease (FORCE)

CompletedOBSERVATIONAL
Enrollment

552

Participants

Timeline

Start Date

November 16, 2016

Primary Completion Date

December 22, 2022

Study Completion Date

December 22, 2022

Conditions
Biliary AtresiaAlagille SyndromeAlpha1 Anti-Trypsin DeficiencyPortal HypertensionLiver FibrosisCholestasis
Interventions
OTHER

Liver Stiffness Measurement (LSM)

LSM will be measured via transient elastography utilizing the non-invasive FibroScan™ ultrasound device. LSM will be measured at Baseline, Year 1 and Year 2 visits.

Trial Locations (13)

15224

Children's Hospital of Pittsburgh, Pittsburgh

19104

Children's Hospital of Philadelphia, Philadelphia

30322

Children's Healthcare of Atlanta (Emory University), Atlanta

46202

Riley Hospital for Children, Indianapolis

60190

Cincinnati Children's Memorial Hospital, Cincinnati

60611

Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago

77030

Texas Children's Hospital (Baylor College of Medicine), Houston

80045

Children's Hospital Colorado, Aurora

84113

University of Utah, Salt Lake City

90027

Children's Hospital Los Angeles, Los Angeles

94143

University of California at San Francisco (UCSF), San Francisco

98105

Seattle Children's Hospital, Seattle

M5G 1X8

Hospital for Sick Children, Toronto

All Listed Sponsors
collaborator

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

lead

Arbor Research Collaborative for Health

OTHER

NCT02922751 - FibroScan™ in Pediatric Cholestatic Liver Disease (FORCE) | Biotech Hunter | Biotech Hunter